Glenmark Pharmaceuticals Limited
GLENMARK
Rang in aandelen
#2739
Glenmark Pharmaceuticals Limited, including its associated entities, is a... Glenmark Pharmaceuticals Limited, including its associated entities, is a global pharmaceutical company specializing in the research, development, production, and marketing of medicinal products. Its operational reach spans India, North America, Latin America, Europe, and other international regions. The company's diverse offerings comprise both branded and generic drug formulations, with a strategic emphasis on therapeutic areas such as dermatology, respiratory conditions, and oncology. Additionally, Glenmark manufactures and supplies a variety of active pharmaceutical ingredients. The company's robust product pipeline includes several investigational therapies. Among its clinical-stage assets are ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody currently in Phase 2b trials for atopic dermatitis; ISB 1302, a HER2 x CD3 bispecific antibody undergoing Phase 1/2 studies for metastatic HER2-positive breast cancer; and ISB 1342, a CD38 x CD3 bispecific antibody in Phase 1 development for relapsed/refractory multiple myeloma. In its preclinical pipeline, Glenmark is advancing ISB 880 for anti-inflammatory applications; the T-cell engagers ISB 1908 and ISB 1909 for oncology indications; ISB 1442, an innate immune engager also targeting oncology; and GRC 39815, a retinoid-related orphan receptor gamma inhibitor aimed at treating chronic obstructive pulmonary disorder (COPD). Among its commercially available products is Ryaltris nasal spray, prescribed for allergic rhinitis. Founded in 1977, Glenmark Pharmaceuticals Limited is headquartered in Mumbai, India.
Aandeelprijs
$24.28
Marktkapitalisatie
$6.85B
Verandering (1 dag)
-0.46%
Verandering (1 jaar)
15.18%
Land
IN
Handel Glenmark Pharmaceuticals Limited (GLENMARK)
Categorie
Healthcare
Omzet van Glenmark Pharmaceuticals Limited (GLENMARK)
Omzet in Jun 2026 TTM: $1.96B
Volgens de laatste financiële rapporten van Glenmark Pharmaceuticals Limited bedraagt de huidige omzet van het bedrijf (TTM) $1.96B. In 2024 behaalde het bedrijf een omzet van $1.52B een stijging ten opzichte van de omzet in het jaar 2023, die $1.42B bedroeg. De omzet is het totale bedrag aan inkomsten dat een bedrijf genereert door de verkoop van goederen of diensten. In tegenstelling tot de winst worden er geen kosten afgetrokken.
Omzetgeschiedenis van Glenmark Pharmaceuticals Limited van 2004 tot 2026
Omzet aan het einde van elk jaar
| Jaar | Omzet | Wijzigen |
|---|---|---|
| 2026 (TTM) | $1.96B | 25.27% |
| 2025 | $1.56B | 3.03% |
| 2024 | $1.52B | 6.93% |
| 2023 | $1.42B | -12.51% |
| 2022 | $1.62B | 8.43% |
| 2021 | $1.49B | 5.68% |
| 2020 | $1.41B | -0.43% |
| 2019 | $1.42B | 1.94% |
| 2018 | $1.39B | -0.46% |
| 2017 | $1.40B | 22.48% |
| 2016 | $1.14B | 8.80% |
| 2015 | $1.05B | 5.93% |
| 2014 | $991.82M | 8.31% |
| 2013 | $915.73M | 15.49% |
| 2012 | $792.91M | 19.82% |
| 2011 | $661.74M | 18.85% |
| 2010 | $556.78M | 33.58% |
| 2009 | $416.81M | -16.99% |
| 2008 | $502.10M | 73.91% |
| 2007 | $288.72M | 69.74% |
| 2006 | $170.10M | 21.35% |
| 2005 | $140.17M | 59.84% |
| 2004 | $87.69M | 0.00% |
Omzet van vergelijkbare bedrijven of concurrenten
| Bedrijf | Omzet | Omzetverschil | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 237.78% |
IN
|
